Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery

The recent SELECT-ACS (Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction) trial then demonstrated the efficacy of inclacumab, a human monoclonal antibody directed against P-selectin, in reducing myocardial damage following percutaneous coronary intervention in patients presenting with acute coronary syndromes (5). All-cause and cardiovascular death 0 (0) 0 (0) 0 (0) Nonfatal myocardial infarction 4 (2.8) 5 (3.4) 9 (3.1) Stroke 1 (0.7) 2 (1.4) 3 (1.0) At least 1 revascularization procedure 15 (10.4) 12 (8.1) 27 (9.2) Hospitalization for heart failure 2 (1.4) 4 (2.7) 6 (2.1) Hospitalization for acute coronary syndrome >24 h 0 (0) 1 (0.7) 1 (0.3) Table 1 Patient Characteristics, Angiographic Efficacy Measures, and Clinical Outcomes Values are mean ± SD or n (%), unless otherwise indicated.SVG = saphenous vein graft.